{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:28Z","timestamp":1791357448973,"version":"4.3.1"},"reference-count":62,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1517\/17425255.2012.693160","type":"journal-article","created":{"date-parts":[[2012,10,15]],"date-time":"2012-10-15T15:15:47Z","timestamp":1350314147000},"page":"873-888","source":"Crossref","is-referenced-by-count":28,"title":["Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability"],"prefix":"10.1517","volume":"8","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[{"name":"Clinical Professor of Psychiatry & Behavioral Sciences, New York Medical College","place":["NY"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,5,25]]},"reference":[{"key":"e_1_3_1_3_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th edition. American Psychiatric Publishing, Inc.; Arlington, Virginia: 2000","edition":"4"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903061309"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01321.x"},{"key":"e_1_3_1_6_1","first-page":"261","article-title":"Paliperidone: the evidence of its therapeutic value in schizophrenia","volume":"2","author":"Kantrowitz J","year":"2008","unstructured":"Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid 2008;2:261-71","journal-title":"Core Evid"},{"key":"e_1_3_1_7_1","unstructured":"FDA. Drug Approval Package. Invega (Paliperidone) Extended-Release Tablets. 30 March 2007. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021999s000_TOC.cfm [Last accessed 16 January 2012]"},{"key":"e_1_3_1_8_1","unstructured":"FDA. Drug Approval Package. Invega (Paliperidone) 3 6 9 12 mg Extended-Release Tablets. 28 May 2009. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022043_invega_toc.cfm [Last accessed 16 January 2012]"},{"key":"e_1_3_1_9_1","unstructured":"Janssen Pharmaceuticals. Invega (paliperidone) Extended-Release Tablets. Available from: http:\/\/www.janssencns.com\/invega-prescribing-information [Last accessed 14 February 2012]"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587630-000000000-00000"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02142.x"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02344.x"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02228.x"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S16077"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02587.x"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.4.4.5"},{"key":"e_1_3_1_18_1","unstructured":"Janssen Pharmaceuticals. Invega Sustenna (paliperidone palmitate) Extended-Release Injectable Suspension for intramuscular use. Available from: http:\/\/www.janssencns.com\/sustenna-prescribing-information [Last accessed 06 March 2012]"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S5734"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01900.x"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1632"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218dcd5"},{"key":"e_1_3_1_23_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YCO.0b013e32835035b2","article-title":"Glutamatergic transmission in schizophrenia: from basic research to clinical practice","volume":"25","author":"Kantrowitz J","year":"2012","unstructured":"Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012;25:96-102","journal-title":"Curr Opin Psychiatry"},{"issue":"11","key":"e_1_3_1_24_1","doi-asserted-by":"crossref","first-page":"o2945","DOI":"10.1107\/S160053681104164X","article-title":"Paliperidone: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]eth-yl}-9-hy-droxy-2-methyl-1,6,7,8,9,9a-hexa-hydro-pyrido[1,2-a]pyrimidin-4-one","volume":"67","author":"Betz R","year":"2011","unstructured":"Betz R, Gerber T, Hosten E, Paliperidone: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]eth-yl}-9-hy-droxy-2-methyl-1,6,7,8,9,9a-hexa-hydro-pyrido[1,2-a]pyrimidin-4-one. Acta Crystallogr Sect E Struct Rep Online 2011;67(Pt 11):o2945-6","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132613"},{"key":"e_1_3_1_26_1","volume-title":"Stahl's essential psychopharmacology","author":"Stahl SM","year":"2008","unstructured":"Stahl SM. Stahl's essential psychopharmacology. 3rd edition. Cambridge University Press; Cambridge: 2008","edition":"3"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900025086"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-1029-z"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009339190"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(10)70664-2"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018275"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1132"},{"key":"e_1_3_1_33_1","unstructured":"Janssen Pharmaceuticals. Risperdal (risperidone) tablets oral solution orally disintegrating tablets. Available from: http:\/\/www.risperdal.com\/prescribing.html [Last accessed 05 March 2012]"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1202265"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1049"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47606"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.09.012"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.003"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.01.017"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05564yel"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181eeb600"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.06.021"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802dda4a"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/11204840-000000000-00000"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S17266"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833db3d8"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328314e1f3"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106914"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.811"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.1010"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1258"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283400d58"},{"key":"e_1_3_1_53_1","article-title":"On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not","author":"Citrome L","year":"2011","unstructured":"Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2011; [Epub ahead of print]","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_3_1_54_1","first-page":"331","article-title":"Non-fatal paliperidone overdose: a case report","volume":"21","author":"Gill JS","year":"2010","unstructured":"Gill JS, Pillai SK, Koh OH, Jambunathan S. Non-fatal paliperidone overdose: a case report. Turk Psikiyatri Derg 2010;21:331-4","journal-title":"Turk Psikiyatri Derg"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2010.10.015"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001076"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00815.x"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.06.030"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.09.011"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2010.01645.x"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182126d83"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0812-7"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-21"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425255.2012.693160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:32:34Z","timestamp":1770913954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425255.2012.693160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,25]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1517\/17425255.2012.693160"],"URL":"https:\/\/doi.org\/10.1517\/17425255.2012.693160","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,25]]}}}